850 related articles for article (PubMed ID: 21923596)
1. Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma.
Boruah PK; Bolesta S; Shetty SM
Pharmacotherapy; 2011 Sep; 31(9):925. PubMed ID: 21923596
[TBL] [Abstract][Full Text] [Related]
2. Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options.
Allegra A; Alonci A; Penna G; Russo S; Gerace D; Greve B; D'Angelo A; Catena S; Musolino C
Hematol Oncol; 2012 Mar; 30(1):41-5. PubMed ID: 21702057
[TBL] [Abstract][Full Text] [Related]
3. Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation.
Wäsch R; Jakob T; Technau K; Finke J; Engelhardt M
Ann Hematol; 2012 Feb; 91(2):287-9. PubMed ID: 21494796
[No Abstract] [Full Text] [Related]
4. Lenalidomide-induced interstitial lung disease.
Chen Y; Kiatsimkul P; Nugent K; Raj R
Pharmacotherapy; 2010 Mar; 30(3):325. PubMed ID: 20180616
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
6. Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients.
Castaneda CP; Brandenburg NA; Bwire R; Burton GH; Zeldis JB
J Clin Oncol; 2009 Jan; 27(1):156-7. PubMed ID: 19047275
[No Abstract] [Full Text] [Related]
7. Fatal toxic epidermal necrolysis associated with minoxidil.
Karaoui LR; Chahine-Chakhtoura C
Pharmacotherapy; 2009 Apr; 29(4):460-7. PubMed ID: 19323621
[TBL] [Abstract][Full Text] [Related]
8. Long-term complete remission in a multiple myeloma patient after Stevens-Johnson syndrome due to lenalidomide therapy.
Musolino C; Alonci A; Catena S; Rizzotti P; Russo S; Rotondo F; Allegra A
Acta Oncol; 2013 Jun; 52(5):1050-1. PubMed ID: 23113590
[No Abstract] [Full Text] [Related]
9. Management of Stevens-Johnson syndrome.
Crosby SS; Murray KM; Marvin JA; Heimbach DM; Tartaglione TA
Clin Pharm; 1986 Aug; 5(8):682-9. PubMed ID: 3742953
[TBL] [Abstract][Full Text] [Related]
10. Stevens-Johnson syndrome as an unusual adverse effect of azithromycin.
Brkljacić N; Gracin S; Prkacin I; Sabljar-Matovinović M; Mrzljak A; Nemet Z
Acta Dermatovenerol Croat; 2006; 14(1):40-5. PubMed ID: 16603101
[TBL] [Abstract][Full Text] [Related]
11. A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma.
Dasanu CA; Alexandrescu DT
Eur J Haematol; 2009 Mar; 82(3):231-4. PubMed ID: 19018868
[TBL] [Abstract][Full Text] [Related]
12. A 2-year-old girl with Stevens--Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulin.
Arca E; Köse O; Erbil AH; Nişanci M; Akar A; Gür AR
Pediatr Dermatol; 2005; 22(4):317-20. PubMed ID: 16060867
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide: Stevens-Johnson syndrome.
Prescrire Int; 2010 Jun; 19(107):125. PubMed ID: 20740722
[No Abstract] [Full Text] [Related]
14. Neutrophilic dermatosis complicating lenalidomide therapy.
Thieu KP; Rosenbach M; Xu X; Kist JM
J Am Acad Dermatol; 2009 Oct; 61(4):709-10. PubMed ID: 19577327
[TBL] [Abstract][Full Text] [Related]
15. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.
Sviggum HP; Davis MD; Rajkumar SV; Dispenzieri A
Arch Dermatol; 2006 Oct; 142(10):1298-302. PubMed ID: 17043184
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
18. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
[TBL] [Abstract][Full Text] [Related]
19. A case of lenalidomide-induced hypersensitivity pneumonitis.
Lerch E; Györik S; Feilchenfeldt J; Mazzucchelli L; Quadri F
Onkologie; 2010; 33(5):249-52. PubMed ID: 20502059
[TBL] [Abstract][Full Text] [Related]
20. Recombinant thrombomodulin improved Stevens-Johnson syndrome with high serum high-mobility group-B1 DNA-binding protein induced by lenalidomide administered to treat multiple myeloma.
Inoue Y; Saito T; Tsuruoka Y; Sato K; Nishio Y; Suzuki Y; Kato M; Isobe Y; Sakai H; Takahashi M; Miura I
Thromb Res; 2013 Oct; 132(4):493-4. PubMed ID: 24050827
[No Abstract] [Full Text] [Related]
[Next] [New Search]
